Is FDG‐PET suitable for evaluating neoadjuvant therapy in non‐small cell lung cancer? Evidence with systematic review of the literature
- 8 March 2010
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 101 (6) , 486-494
Abstract
Background: Neoadjuvant therapy response assessment is crucial in patients with non‐small cell lung cancer (NSCLC). FDG‐PET has emerged as a valuable tool for defining therapy response assessment in other tumours.Aim: To systematically review publications appearing in the literature describing induction therapy response assessment with FDG‐PET in NSCLC.Methods: We performed a bibliographic search and selected only prospective studies in order to include the highest levels of evidence.Results: Nine of 497 potentially relevant publications were selected. The ranges of sensitivity, specificity, positive predictive value and negative predictive value for primary tumour response assessment were 80–100%, 0–100%, 42.9–100%, and 66.7–100%, respectively. Pooling data for N2 restaging after neoadjuvant response the overall sensitivity was 63.8% (95% CI, 53.3–73.7%) and overall specificity was 85.3% (95% CI, 80.4–89.4%).Conclusion: The results of the analysis do not support the use of FDG‐PET as the only re‐assessment tool for mediastinal lymph node evaluation for routine clinical use. FDG‐PET seems to predict primary tumour response to induction therapy but it could not be shown by pooling analysis. J. Surg. Oncol. 2010; 101:486–494.Keywords
This publication has 27 references indexed in Scilit:
- Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2008
- Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung CancerJournal of Nuclear Medicine, 2007
- Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancerCancer, 2007
- Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancerLung Cancer, 2007
- Correlation of PET/CT Findings and Histopathology after Neoadjuvant Therapy in Non-Small Cell Lung CancerOncology, 2007
- Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non–Small-Cell Lung Cancer: A Leuven Lung Cancer Group StudyJournal of Clinical Oncology, 2006
- Restaging patients with N2 (stage IIIa) non–small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective studyThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Positron-Emission Tomography and Assessment of Cancer TherapyNew England Journal of Medicine, 2006
- Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999